- Nationwide storytelling movement to showcase diverse voices of
the type 1 diabetes community, including internationally recognized
stars Usher, Robin Arzón, and Adam
Schefter, to share experiences and encourage people to get
screened
- The 1 Pledge movement commences with surround-sound event in
New York City's Times Square;
continues throughout the year with events and social
storytelling
- Screening for type 1 diabetes can detect the disease before
noticeable symptoms arise1; people can pledge to get
themselves and their family screened at The1Pledge.com
BRIDGEWATER, N.J., Nov. 1, 2023
/PRNewswire/ -- Sanofi, a leader in diabetes care, today launched
"The 1 Pledge" movement, a nationwide education campaign urging
families to get screened for type 1 diabetes so that those who will
eventually be affected by the disease can begin to prepare as soon
as possible.
"The 1 Pledge" movement will be driven by widely known
celebrities, including musician and philanthropist Usher Raymond
IV, whose child was diagnosed with type 1 diabetes at age 6.
Type 1 diabetes can be a lifechanging diagnosis that can be
detected before the onset of symptoms,1 which can
be diagnosed at any age but usually develops and is diagnosed
during childhood and young adulthood.2
Approximately 1.45 million Americans have type 1
diabetes3 and many families with children who have type
1 diabetes say that knowing about the disease as early as
possible allows time for important education, preparation and
coaching.1
USHER
Award-winning singer,
songwriter, actor, entrepreneur, and philanthropist
"Since the day my child was diagnosed with type 1
diabetes, the condition is something I never stop thinking about.
Had we detected my child's type 1 diabetes before their diagnosis
it could have given us valuable time to prepare. My child's bravery
inspires me every day and my hope in partnering with Sanofi is to
inspire other families in this important work. Do not wait until
you see symptoms. Pledge to screen for type 1 diabetes today so you
can prepare for what could come."
Other participants include Robin Arzón, Vice President of
Fitness Programming and Head Instructor at Peloton and a type 1
diabetes patient herself; and journalist Adam Schefter, whose wife Sharri Maio lives with type 1 diabetes and
has been a longtime advocate for raising awareness around the
disease.
Robin Arzón
Vice President of
Fitness Programming and Head Instructor at Peloton, ultramarathoner
and best-selling author
"I was diagnosed with type 1 diabetes in my early thirties, and
in an instant my life and daily routine changed. A diagnosis like
this can be scary, even shocking, for so many and their families,
but I believe in the power of education and awareness. The more we
know, the more we can do. The 1 Pledge is very personal for me, and
I encourage everyone to screen for type 1 diabetes."
Adam Schefter
Sports
journalist
"My wife Sharri was diagnosed with type 1 diabetes over 20 years
ago. She is the rock of our family, even while navigating this
condition. We have been advocating for awareness around type 1
diabetes for nearly as many years as she has been living with
diabetes. I built my career on the power of early knowledge and we
joined this movement because we believe that a decision today to
screen for type 1 diabetes could help change you or your family's
future. That's also why we have had our daughter screened for type
1. We know from our experience that our children are at a higher
risk of developing type 1 diabetes because there is familial
history, so we are pledging to take action. Join us in this
powerful movement today."
By using personal stories, these celebrities aim to share the
importance of screening, education and preparation for type 1
diabetes. Patients, caregivers and other influencers are slated to
add their voices to the effort as the movement accelerates.
Olivier Bogillot
Head of U.S.
General Medicines, Sanofi
"For many families, a type 1 diabetes diagnosis is sudden and
life changing. With The 1 Pledge campaign, our aim is to raise
awareness that type 1 diabetes can be detected early and that
screening is available and may help to better prepare families to
manage the disease. Sanofi remains committed to help people living
with diabetes and to bring innovation to this community."
Type 1 diabetes is an autoimmune disease in which the pancreas
does not make enough insulin and people with type 1 diabetes
eventually rely on insulin.4 Type 1 diabetes can present
itself in first- and second-degree relatives – in fact, if someone
in a family has type 1 diabetes, it is approximately up to 15 times
more likely to manifest in someone else in the family5 –
but this is not always the case: approximately 90% of people who
develop type 1 diabetes do not have a family history.6
Type 1 diabetes also frequently presents with life-threatening
complications.7 Early screening is important because
blood tests can detect autoantibodies associated with type 1
diabetes before serious crises occur.1 While type 1
diabetes can't be prevented,3 taking the step to screen
may give people more time to prepare.
Making the decision to get screened and get one's family
screened could give families time to get educated and be prepared
early. People can pledge to get screened for type 1 diabetes today
at The1Pledge.com, and follow the movement on social media using
#ScreenforType1. Sanofi encourages people interested in learning
more about screening or type 1 diabetes to speak to their
doctor.
Usher, Robin Arzón, Adam Schefter
and the other social media personalities that are participating are
paid spokespeople for Sanofi.
About Sanofi
We are an innovative global healthcare
company, driven by one purpose: we chase the miracles of science to
improve people's lives. Our team, across some 100 countries, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Evan Berland | + 1
215 432 0234 | evan.berland@sanofi.com
Investor Relations
Eva
Schaefer-Jansen | + 33 7 86 80 56 39 |
eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612
7239 | felix.lauscher@sanofi.com
Priya Nanduri | +1 617
764 6418 | priya.nanduri@sanofi.com
Nathalie Pham | + 33 7
85 93 30 17 | nathalie.pham@sanofi.com
Sanofi Forward-Looking Statements
This press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi's
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31,
2022. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
References
- Beyond Type 1. Screening for Type 1
Diabetes. https://beyondtype1.org/screening-for-type-1-diabetes/.
Accessed October 2023.
- CDC. What is Type 1 Diabetes?
https://www.cdc.gov/diabetes/basics/what-is-type-1-diabetes.html.
Accessed October 2023.
- Beyond Type 1. Type 1 Diabetes
Statistics. https://beyondtype1.org/type-1-diabetes-statistics.
Accessed October 2023.
- JDRF. Diabetes 101. https://www.jdrf.org/t1d-resources/about/.
Accessed October 2023.
- Van Belle T, et al. Type 1 Diabetes: Etiology, Immunology,
and Therapeutic Strategies. Physiological Reviews. 2011;91:79-118.
https://doi.org/10.1152/physrev.00003.2010.
- Steck A & Rewers M. Genetics of Type 1 Diabetes. Clinical
Chemistry. 2011;57(2):176-185.
https://doi.org/10.1373/clinchem.2010.148221.
- Nakhla M, et al. Diabetic Ketoacidosis at the Time of Diagnosis
of Type 1 Diabetes in Children. JAMA Pediatrics.
2021;175(5):518-520.
https://doi.org/10.1001/jamapediatrics.2020.5512.
View original
content:https://www.prnewswire.com/news-releases/sanofi-launches-the-1-pledge-movement-to-drive-early-screening-for-type-1-diabetes-in-the-us-301973026.html
SOURCE Sanofi